Caroline Dix
Overview
Explore the profile of Caroline Dix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tran H, Dix C, Bird R, Chunilal S, Brighton T, Reynolds J, et al.
Am J Hematol
. 2024 Dec;
100(3):516-519.
PMID: 39715073
No abstract available.
2.
Biggs K, Dix C, Shiely F, Treweek S, Shepherd V, Lane A, et al.
NIHR Open Res
. 2024 Sep;
4:12.
PMID: 39297143
Background: Participants in clinical trials often do not reflect the populations that could benefit from the treatments being investigated. There are known barriers to trial participation for under-served groups, but...
3.
Dix C, Hunt B
J Thromb Haemost
. 2024 Sep;
22(12):3346-3354.
PMID: 39260741
Cerebral venous sinus thrombosis (CVST) is an uncommon site of venous thromboembolism. CVST more commonly affects younger people and women, in stark contrast to other forms of venous thrombosis in...
4.
Dix C, Doyle A, Breen K, Hunt B
Thromb Haemost
. 2024 Aug;
PMID: 39102861
Background: Individuals with inherited antithrombin deficiency (IATD) have a high risk of venous thromboembolism (VTE). Most VTEs are managed with direct oral anticoagulants (DOACs), but the utility of DOACs in...
5.
Dix C, McFadyen J, Tran H
Thromb Res
. 2024 Apr;
237:148-153.
PMID: 38603817
Optimal management of cardiovascular disease (CVD) in people with haemophilia (PWH) is a growing issue, given the continuing improvement in life expectancy among PWH. The evolving treatment paradigms targeting higher...
6.
Dix C, Dolan G, Hunt B
J Thromb Haemost
. 2024 Feb;
22(5):1304-1312.
PMID: 38309435
Revolutionary advances in the treatment of hemophilia has led to a significant improvement in life expectancy. Associated with this has been an increase in age-related diseases especially atherosclerotic cardiovascular disease...
7.
Sultan M, Kong Y, Story C, Caterson H, Dix C, Gad F, et al.
Intern Med J
. 2023 Nov;
54(1):43-53.
PMID: 37926861
Background: Severe COVID-19 causes acute inflammation, which is complicated by venous thromboembolism events (VTE). However, it is unclear if VTE risk has evolved over time since the COVID-19 outbreak. Aims:...
8.
Dix C, Moloney M, Tran H, McFadyen J
Thromb Haemost
. 2023 Oct;
124(5):387-398.
PMID: 37816389
Gender-affirming therapy involves the use of hormones to develop the physical characteristics of the identified gender and suppressing endogenous sex hormone production. Venous thromboembolism (VTE) is a known risk of...
9.
Dix C, Bortz H, da Gama M, Treloar M, Reynolds M, Ramanan R, et al.
Int J Pharm Pract
. 2023 Jul;
31(5):528-533.
PMID: 37494677
Objectives: To assess adherence and persistence to the direct factor Xa inhibitor oral anticoagulants in the community following newly diagnosed venous thromboembolism (VTE). Methods: We retrospectively reviewed community pharmacy dispensing...
10.
Kershaw G, Dix C
Methods Mol Biol
. 2023 May;
2663:589-595.
PMID: 37204738
Emicizumab is a bi-specific antibody that in recent years has been introduced in many countries as a prophylactic agent for bleed prevention in cases of severe hemophilia A, and in...